Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v20.i5-6.90
pages 357-371

Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy

Jason H. Tang
Department of Pathology, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA
David Chia
Department of Pathology, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA


Non-small cell lung cancer (NSCLC) still dominates cancer-related deaths in America. Despite this, new discoveries and advancements in technology are helping with the detection and treatment of NSCLC. The discovery of circulating tumor DNA in blood and other biofluids is essential for the creation of a DNA biomarker. Limitations in technology and sequencing have stunted assay development, but with recent advancements in the next-generation sequencing, droplet digital PCR, and EFIRM, the detection of mutations in biofluids has become possible with reasonable sensitivity and specificity. These methods have been applied to the detection of mutations in NSCLC by measuring the levels of circulating tumor DNA. ALK fusion genes along with mutations in EGFR and KRAS have been shown to correlate to tumor size and metastasis. These methods allow for noninvasive, affordable, and efficient diagnoses of oncogenic mutations that overcome the issues of traditional biopsies. These issues include tumor heterogeneity and early detection of cancers with asymptomatic early stages. Early detection and treatment remain the best way to ensure survival. This review aims to describe these new technologies along with their application in mutation detection in NSCLC in order to proactively utilize targeted anticancer therapy.

Articles with similar content:

The Importance of Cancer Stem Cells in Gastrointestinal Cancers
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Duygu Altinok Dindar, Ahmet Ozet, Gulsah Albayrak
Druggable Targets in Pancreatic Adenocarcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Enrico Mini, Renato Tassi
Genes Associated with Human Cancers: Their Expressions, Features, Functions, and Significance
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 3
Maddaly Ravi, Bellona Sahu, Divya K. Mohan
Circulating Tumor Cells in Breast Cancer Patients
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Lily Valad, Carolyn Hall, Anthony Lucci
miRNA: A Diagnostic and Therapeutic Tool for Pancreatic Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 3
Muhammad Imran Qadir, Arooj Faheem